消化道溃疡患者奥美拉唑代谢相关基因CYP2C19的多态性分布The Polymorphism Distribution of Omeprazole Mechanism Related CYP2C19 Gene in Patients of Peptic Ulcer
任凌雁,袁军,陈琨,骆姝琳,李伟,令狐克燕
REN Lingyan,YUAN Jun,CHEN Kun,LUO Shulin,LI Wei,LINGHU Keyan
摘要(Abstract)：
目的:分析奥美拉唑代谢相关基因CYP2C19基因在消化道溃疡患者中的多态性分布。方法:选取消化道溃疡患者23例为研究对象,采用基因芯片的方法检测CYP2C19的基因多态性,并分析CYP2C19基因型总体分布和性别分布。结果:CYP2C19基因型(636GG,681GG)、(636GG,681GA)、(636GA,681GG)、(636GG,681AA)、(636GA,681GA)及(636AA,681GG)携带率分别为39.1%、30.4%、13%、8.7%、8.7%、0;CYP2C19基因快代谢型占39.1%,中代谢型占43.5%,慢代谢型占17.4%;不同性别在CYP2CI9基因分型上差异无统计学意义。结论:检测CYP2C19基因型可为奥美拉唑个体化用药提供指导。
Objective: To investigate the polymorphism distribution of omeprazole mechanism related CYP2C19 gene in patients of peptic ulcer. Method: Twenty-three patients of peptic ulcer were selected,then adopting gene chip to test the polymorphism of CYP2C19. Analyzing the general distribution and gender distribution of CYP2C19 genotype. Results: CYP2C19 genotype( 636 GG,681GG),( 636 GG,681GA),( 636 GA,681GG),( 636 GG,681AA),( 636 GA,681GA) and( 636 AA,681GG)carrier rates were respectively 39. 1%,30. 4%,13%,8. 7%,8. 7%,0; the extensive metabolizer,intermediate metabolizer,poor metabolizer of CYP2C19 gene were 39. 1%,43. 5% and 17. 4%; the gender differences in CYP2C19 had no statistical significance. Conclusion: Testing of CYP2C19 might be useful in suggesting medication of omeprazole.
关键词(KeyWords)：
消化性溃疡;奥美拉唑;CYP2C19基因;多态性,单核苷酸
peptic ulcer;omeprazole;CYP2C19 gene;polymorphism,single nucleotide
基金项目(Foundation): 黔科平台[2010]4005;; [2010]筑科技合同字3-1号;; 黔科合sy[2010]3132号
作者(Author):
任凌雁,袁军,陈琨,骆姝琳,李伟,令狐克燕
REN Lingyan,YUAN Jun,CHEN Kun,LUO Shulin,LI Wei,LINGHU Keyan
DOI: 10.19367/j.cnki.1000-2707.2015.10.013
参考文献(References)：
- [1]张鉴,彭向,李军,等.质子泵抑制剂的代谢与细胞色素P450[J].山东医药,2005(2):20.
- [2]牛春燕,罗金燕.CYP2C19基因多态性与质子泵抑制剂对消化性溃疡患者抑酸效应的关系[J].世界华人消化杂志,2007(19):2551-2155.
- [3]江尔胜,汪涓,孙启泉,等.奥美拉唑体内药物分析[J].山东医药工业,2003(4):12.
- [4]谢婧,胡欣,杨丽萍.CYP2C19*17多态性对氯吡格雷临床疗效影响的系统评价[J].中国循证医学杂志,2014(3):271-276.
- [5]李鹏飞,杨海波,赵荫涛,等.冠心病介入患者氯吡格雷药物代谢相关基因CYP2C19的多态性分布[J].中国实用医刊,2014(10):64-65.
- [6]Hulot JS,Hajjar R,Montalescot G.Clopidogrel and CYP2C19 testing:ready for clinical prime time[J],Clin Chem,2012(1):154-157.
- [7]梁艳,刘振华,白清清,等.CYP2C1基因型与奥美拉唑治疗消化道溃疡疗效的相关性[J].武警医学,2014(2):142-147.
- [8]陈珲,蔡泓敏,冯端浩,等.CYP2C9和CYP2C19基因多态性对药物代谢的影响及个体化用药研究进展[J].中国药物应用与检测,2014(4):240-243.
- [9]严非,夏春华,熊玉卿.CYP2C19基因多态性对药物代谢的影响及其个体化用药[J].中国临床药理学与治疗学,2010(8):949-953.
文章评论(Comment)：
|
||||||||||||||||||
|
||||||||||||||||||